A team of scientists from La Trobe University has shown a protein found in a tobacco plant has the potential to fight life-threatening infectious diseases
The scientific discovery, published in the prestigious journal Nature Communications could lead to the development of a new class of antibiotics and meet the challenge of rising antibiotic resistance.
Dr Mark Hulett and Dr Marc Kvansakul from the La Trobe Institute for Molecular Science said their team had demonstrated the peptide NaD1 found in the flowers of the ornamental tobacco plant Nicotiana alata has infection-busting qualities.
“Infectious diseases are a major global health problem, accounting for more than one in eight deaths and mortality rates are predicted to skyrocket over the next 30 years,” Dr Hulett said.
“Antibiotic resistance at the current rate will eventually lead to the exhaustion of effective long-term drug options. It’s imperative we develop new antibiotic treatments.”
Using the power of the Australian Synchrotron, the team led by Dr Hulett and Dr Kvansakul have shown in atomic detail how the tobacco plant peptide can target and destroy the micro-organism responsible for a dangerous fungal infection.
The peptide perforates the parachute-like outer layer of Candida albicans cells, ripping them apart and causing them to explode and die.
“They act in a different way to existing antibiotics and allow us to explore new ways of fighting infections.
“It’s an exciting discovery that could be harnessed to develop a new class of life-saving antimicrobial therapy to treat a range of infectious diseases, including multi-drug-resistant golden staph, and viral infections such as HIV, Zika virus, Dengue and Murray River Encephalitis.”
In 2014, Dr Hulett and Dr Kvansakul found NaD1 could also be effective in killing cancer cells.
Candida albicans is responsible for life-threatening infections in immune-compromised patients, including those diagnosed with cancer and transplant recipients. There are limited effective antibiotics available to treat the infection.
Nicotiana alata flowers naturally produce potent anti-fungal molecules for protection against disease. The plant is related, but different, to tobacco plants grown for commercial use.
Learn more: La Trobe’s infection-busting discovery
The Latest on: Antimicrobial therapy
via Google News
The Latest on: Antimicrobial therapy
- Fluoroquinolone use declines prior to FDA warning in Southeastern US hospitals on October 6, 2018 at 3:23 am
Their analysis — an interrupted time series approach — looked at the long-term trends of antimicrobial use and the impact of the 2016 FDA safety announcement. They measured FQ and alternative antibiot... […]
- An electronic antimicrobial stewardship intervention reduces inappropriate parenteral antibiotic therapy on October 3, 2018 at 1:28 pm
To send this article to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and De... […]
- IDF combats antimicrobial resistance in dairy on September 25, 2018 at 2:54 am
Antimicrobial resistance (AMR ... The IDF’s annual Animal Health Report suggested a system of selective dry-cow therapy, as opposed to a blanket treatment, could prevent AMR – and prevent it from bein... […]
- Antimicrobial therapy can prevent sepsis in pneumonia patients on April 16, 2018 at 8:04 am
Antimicrobial therapy targeting specific cells in the immune system could prevent sepsis and life-threatening disease in people suffering from pneumonia, new research led by the University of Leiceste... […]
- Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel on April 9, 2018 at 5:48 am
LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Sonoma Pharma, Inc. (NASDAQ: SNOA). If you want access to this report all you need to do is ... […]
- Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel on April 5, 2018 at 4:25 am
April 05, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc. PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceuti... […]
- FDA clears Sonoma Pharma's antimicrobial post-therapy gel on April 5, 2018 at 4:19 am
The FDA grants 510(k) clearance for Sonoma Pharmaceuticals' (NASDAQ:SNOA) antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therap... […]
- Failure of dual antimicrobial therapy for gonorrhea reported on June 23, 2016 at 11:40 am
(HealthDay)—In a case report published in the June 23 issue of the New England Journal of Medicine, dual antimicrobial therapy failure is described in the treatment of gonorrhea. Helen Fifer, B.M.B.S. ... […]
- NovaBay: Tomorrow's Staple In Antimicrobial Therapy? on May 2, 2012 at 1:55 pm
NovaBay Pharmaceuticals (NYSEMKT:NBY) is developing products that represent a microcosm of the Johnson & Johnsons, Strykers and Medtronics of the world -- non-discretionary healthcare items that will ... […]
via Bing News